6.58
+0.02(+0.30%)
Currency In USD
| Previous Close | 6.56 |
| Open | 6.64 |
| Day High | 6.7 |
| Day Low | 6.4 |
| 52-Week High | 15.47 |
| 52-Week Low | 3.76 |
| Volume | 805,149 |
| Average Volume | 1.04M |
| Market Cap | 613.29M |
| PE | -1.51 |
| EPS | -4.35 |
| Moving Average 50 Days | 6.9 |
| Moving Average 200 Days | 6.43 |
| Change | 0.02 |
If you invested $1000 in Myriad Genetics, Inc. (MYGN) 10 years ago, it would be worth $158.75 as of January 10, 2026 at a share price of $6.58. Whereas If you bought $1000 worth of Myriad Genetics, Inc. (MYGN) shares 5 years ago, it would be worth $258.65 as of January 10, 2026 at a share price of $6.58.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 05, 2026 9:15 PM GMT
SALT LAKE CITY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Sam Raha, president and CEO, will present at the 44th Annual J.P. Morgan H
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium
GlobeNewswire Inc.
Dec 09, 2025 2:00 PM GMT
New data will be presented about Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer TestSALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
GlobeNewswire Inc.
Nov 25, 2025 9:15 PM GMT
Actionable offering helps enable earlier, more personalized breast cancer interventionsBOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView, today announced a joint